Clinical Research Directory
Browse clinical research sites, groups, and studies.
ABA-101 in Participants With Progressive Multiple Sclerosis
Sponsor: Abata Therapeutics
Summary
This study will test the safety and effects of ABA-101 when given as a single dose to participants with progressive multiple sclerosis. It is the first study of this treatment in humans. After safety is demonstrated with a low dose of ABA-101, a higher dose will be evaluated.
Official title: A Phase 1 Open-label, Single Ascending Dose Study of ABA-101 in Participants With Progressive Multiple Sclerosis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2024-09-11
Completion Date
2027-02
Last Updated
2025-07-03
Healthy Volunteers
No
Conditions
Interventions
ABA-101
ABA-101 is a TCR engineered, autologous regulatory T cell (Treg) therapy
Locations (3)
Johns Hopkins University
Baltimore, Maryland, United States
Rutgers, Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States
Cleveland Clinic Mellen Center
Cleveland, Ohio, United States